Literature DB >> 7966578

An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences.

E Vicenzi1, D S Dimitrov, A Engelman, T S Migone, D F Purcell, J Leonard, G Englund, M A Martin.   

Abstract

Nonoverlapping deletions that eliminated the 5' (HIV-1US/603del), middle (HIV-1U5/206del), and 3' (HIV-1U5/604del) thirds of the U5 region of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR) were studied for their effects on virus replication (transient transfection of HeLa cells) and infectivity (T-cell lines and peripheral blood mononuclear cells). All three mutants exhibited a wild-type phenotype in directing the production and release of virus particles from transfected HeLa cells. In infectivity assays, HIV-1U5/206del was usually indistinguishable from wild-type virus whereas HIV-1U%/603del was unable to infect human peripheral blood mononuclear cells or MT4 and CEM cells. Investigations of HIV-1U5/603del particles revealed a packaging defect resulting in a 10-fold reduction of encapsidated genomic RNA. The HIV-1U5/604del mutant either was noninfectious or exhibited delayed infection kinetics, depending on the cell type and multiplicity of infection. Quantitative competitive PCR indicated that HIV-1U5/604del synthesized normal amounts of viral DNA in newly infected cells. During the course of a long-term infectivity assay, a revertant of the HIV-1U5/604del mutant that displayed rapid infection kinetics emerged. Nucleotide sequence analysis indicated that the original 26-nucleotide deletion present in HIV-1U5/604del had been extended an additional 19 nucleotides in the revertant virus. Characterization of the HIV-1U5/604del mutant LTR in in vitro integration reactions revealed defective 3' processing and strand transfer activities that were partially restored when the revertant LTR substrate was used, suggesting that the reversion corrected a similar defect in the mutant virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966578      PMCID: PMC237250          DOI: 10.1128/JVI.68.12.7879-7890.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Interaction between retroviral U5 RNA and the T psi C loop of the tRNA(Trp) primer is required for efficient initiation of reverse transcription.

Authors:  A Aiyar; D Cobrinik; Z Ge; H J Kung; J Leis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

3.  A mutation at one end of Moloney murine leukemia virus DNA blocks cleavage of both ends by the viral integrase in vivo.

Authors:  J E Murphy; S P Goff
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

4.  HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer.

Authors:  A Engelman; K Mizuuchi; R Craigie
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

5.  Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage.

Authors:  C Vink; D C van Gent; Y Elgersma; R H Plasterk
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

6.  Effect of internal viral sequences on the utility of retroviral vectors.

Authors:  D Armentano; S F Yu; P W Kantoff; T von Ruden; W F Anderson; E Gilboa
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

7.  Avian retroviral RNA encapsidation: reexamination of functional 5' RNA sequences and the role of nucleocapsid Cys-His motifs.

Authors:  R Aronoff; A M Hajjar; M L Linial
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1.

Authors:  K Fujita; J Silver; K Peden
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Both substrate and target oligonucleotide sequences affect in vitro integration mediated by human immunodeficiency virus type 1 integrase protein produced in Saccharomyces cerevisiae.

Authors:  A D Leavitt; R B Rose; H E Varmus
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

10.  Quantitation of human immunodeficiency virus type 1 infection kinetics.

Authors:  D S Dimitrov; R L Willey; H Sato; L J Chang; R Blumenthal; M A Martin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more
  38 in total

1.  Substrate sequence selection by retroviral integrase.

Authors:  H Zhou; G J Rainey; S K Wong; J M Coffin
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Characterization of a replication-defective human immunodeficiency virus type 1 att site mutant that is blocked after the 3' processing step of retroviral integration.

Authors:  H Chen; A Engelman
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity.

Authors:  C Liang; X Li; L Rong; P Inouye; Y Quan; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

5.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Structure-function relationships of the initiation complex of HIV-1 reverse transcription: the case of mutant viruses using tRNA(His) as primer.

Authors:  Mickaël Rigourd; Valérie Goldschmidt; Fabienne Brulé; Casey D Morrow; Bernard Ehresmann; Chantal Ehresmann; Roland Marquet
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

7.  The primer binding site on the RNA genome of human and simian immunodeficiency viruses is flanked by an upstream hairpin structure.

Authors:  B Berkhout
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

8.  Nef alleles from human immunodeficiency virus type 1-infected long-term-nonprogressor hemophiliacs with or without late disease progression are defective in enhancing virus replication and CD4 down-regulation.

Authors:  Andrea Crotti; Francesca Neri; Davide Corti; Silvia Ghezzi; Silvia Heltai; Andreas Baur; Guido Poli; Elena Santagostino; Elisa Vicenzi
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

9.  A mutation in integrase can compensate for mutations in the simian immunodeficiency virus att site.

Authors:  Z Du; P O Ilyinskii; K Lally; R C Desrosiers; A Engelman
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

10.  Genetic analysis of a unique human immunodeficiency virus type 1 (HIV-1) with a primer binding site complementary to tRNAMet supports a role for U5-PBS stem-loop RNA structures in initiation of HIV-1 reverse transcription.

Authors:  S M Kang; C D Morrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.